MorphoSys develops and commercializes therapeutic antibodies for the treatment of cancer, inflammatory and autoimmune diseases.Read more
MorphoSys's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 9B. Over the last two quarters, MorphoSys's revenue has grown by 203.8%. Specifically, in Q4 2020's revenue was $78.2M; in Q3 2020, it was $25.7M.